Jefferies Assumes Nektar Therapeutics at Hold, Lowers Price Target of $4
Jefferies analyst Roger Song assumes Nektar Therapeutics (NASDAQ:NKTR) with a Hold rating and lowers Price Target of $4.
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
Nektar Therapeutics (NASDAQ:NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce,…
The Daily Biotech Pulse: Protagonist’s Ulcerative Colitis Study Disappoints, Gilead’s Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida’s Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours:
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday.
Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views
U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.
34 Stocks Moving In Monday’s Mid-Day Session
Gainers
Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.
Why Nektar Shares Are Down Almost 35%
Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in collaboration with Bristo,” according to BofA Securities.
Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points
U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday.